Baxter International Reports Strong Q2 Earnings with Sales Growth and Guidance Hike
Baxter International (NYSE:BAX) reported second-quarter results that exceeded expectations in August 2026. The company achieved a 5% sales increase to $3 billion, driven by strong performance from its Advanced Surgery segment (+12%) and drug compounding services. Adjusted earnings per share were $0.56, including an unexpected $75 million tariff refund under the IEEPA that added about $0.11 per share. Baxter raised its full-year 2026 outlook to reflect stronger-than-expected performance. It now anticipates organic sales growth of 2%–3%, with adjusted earnings between $1.95 and $2.15 per share. The company is also focused on reducing debt, aiming for a net leverage ratio of around three times by year-end. Despite the positive results, Baxter faces challenges in its Infusion Therapies & Platforms segment due to ongoing issues with Novum IQ pump shipments being held while verification testing continues.
Tickers: $BAX
Topics: financial_performance guidance_update medical_devices